Phase 3 Clinical Trials With Primary Completion Dates in March 2020

This is a list of Phase 3 trials with primary completion dates in March 2020 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
ABSCF AB Science S.A. 2020-03-01 Phase 3 NCT03761225 Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer
AMPE Ampio Pharmaceuticals, Inc. 2020-03-01 Phase 3 NCT03988023 Study of Ampion for the Treatment of Pain and Function in Patients With Severe Osteoarthritis of the Knee.
AXSM Axsome Therapeutics, Inc. 2020-03-01 Phase 3 NCT04163185 Initiating Early Control of Migraine Pain and Associated Symptoms
AXSM Axsome Therapeutics, Inc. 2020-03-01 Phase 3 NCT02741791 A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder
BPMUF Basilea Pharmaceutica AG 2020-03-01 Phase 3 NCT03439124 Ceftobiprole in the Treatment of Pediatric Patients With Pneumonia
CARA Cara Therapeutics, Inc. 2020-03-01 Phase 3 NCT03998163 CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
CARA Cara Therapeutics, Inc. 2020-03-01 Phase 3 NCT03636269 CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
CRBP Corbus Pharmaceuticals Holdings, Inc. 2020-03-01 Phase 3 NCT03398837 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
CYAD Celyad SA 2020-03-01 Phase 3 NCT02317458 Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-2) Trial - THE CHART-2 TRIAL
HESG Health Sciences Group, Inc. 2020-03-01 Phase 3 NCT04249336 Clinical Efficacy Of BioMin F, Colgate Sensitive Pro-Relief And Sensodyne Rapid Action Dentifrices In DH
MESO Mesoblast Limited 2020-03-01 Phase 3 NCT02412735 Placebo-controlled Study to Evaluate Rexlemestrocel-L Alone or Combined With Hyaluronic Acid in Subjects With Chronic Low Back Pain
MGNX MacroGenics, Inc. 2020-03-01 Phase 3 NCT02492711 Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
NEPH Nephros, Inc. 2020-03-01 Phase 3 NCT02476279 Stent vs. Indomethacin for Preventing Post-ERCP Pancreatitis
NVAX Novavax, Inc. 2020-03-01 Phase 3 NCT04120194 Phase 3 Pivotal Trial of NanoFlu™ in Older Adults
OBSV ObsEva SA 2020-03-01 Phase 3 NCT03070899 Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids
ONPH Oncology Pharma Inc. 2020-03-01 Phase 3 NCT00433589 Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes
QURE uniQure N.V. 2020-03-01 Phase 3 NCT03569891 HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients
RIGL Rigel Pharmaceuticals, Inc. 2020-03-01 Phase 3 NCT02077192 Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
SCYX SCYNEXIS, Inc. 2020-03-01 Phase 3 NCT03987620 Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis
SUPN Supernus Pharmaceuticals, Inc. 2020-03-01 Phase 3 NCT02691182 Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4)
SYNH Syneos Health, Inc. 2020-03-01 Phase 3 NCT02810444 Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID
TGTX TG Therapeutics, Inc. 2020-03-01 Phase 3 NCT02301156 Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)